Osimertinib (Figure 26) (AZD9291, Tagrisso®) is the first third-generation EGFR TKI approved as first-line therapy for EGFR-positive activating mutations (L858R and del19), NSCLC, and metastatic EGFRT790M-positive NSCLC patients detected by an approved FDA test [190]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.